Author

Krish Skandha Gopalan

VIB-KU Leuven Center for Cancer BiologyORCID 0009-0003-3629-3597Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell-cell communication· 2 Research Focus:differential expression· 2 Organism:mouse· 2 Assay:scRNA-seq· 2 Research Focus:cell type annotation· 1 Research Focus:clustering· 1 Approach:deep learning· 1 Approach:experimental assay· 1

Frequent Co-Authors

Carla Pallarés-MoratallaiD· 2 shared Frederik De SmetiD· 2 shared Gabriele BergersiD· 2 shared Linqian WengiD· 2 shared Mélanie GuyotiD· 2 shared Abhishek Dinkarnath GargiD· 1 shared Annette T. ByrneiD· 1 shared Bernhard RobliD· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 41 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Carla Pallarés-MoratallaORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintApr 28, 2026

Microglial lipid signaling drives glioblastoma invasion and represents a therapeutic vulnerability

Carla Pallarés-Moratalla, Mélanie Guyot, Krish Skandha Gopalan…·Gabriele Bergers

This study identifies a lipid-mediated signaling pathway driven by microglia that promotes glioblastoma invasion and shows that targeting this pathway can suppress tumor invasion.

DOI 10.64898/2026.04.24.720633

mousescRNA-seq

𝕏 PostBluesky

Cancer BiologyNeuro-OncologyPeer-reviewedJan 27, 2026

Distinct tumor immune microenvironmental (TIME) landscapes drive divergent immunotherapy responses in glioblastoma

Linqian Weng, Krish Skandha Gopalan, Mélanie Guyot…·Gabriele Bergers

This study identifies three distinct tumor immune microenvironment (TIME) subtypes in glioblastoma (GBM) with divergent responses to immunotherapy, supporting personalized treatment strategies.

4 citationstop 1%

humanmouse

𝕏 PostBluesky